Multiple Sclerosis Therapeutics Market By Drug Class (Immunomodulators, Oral Agents, Monoclonal Antibodies, Others); By Route of Administration (Oral, Injectable, Intravenous Infusion); By Disease Type (Relapsing-Remitting MS, Secondary Progressive MS, Primary Progressive MS); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Multiple Sclerosis Therapeutics Market: Patient Conversion, Anti-CD20 Revenue Concentration and Progressive-MS Expansion Reshape Competition

The Global Multiple Sclerosis Therapeutics Market was valued at USD 30.65 billion in 2025 and is projected to reach USD 48.58 billion by 2032, growing at a CAGR of 6.8%, according to Strategic Market Research.

 

The market serves a global population of approximately 2.9 million people living with multiple sclerosis. Incidence across 81 reporting countries reached 2.1 cases per 100,000 people annually in the Atlas of MS 2023 update, equivalent to one new diagnosis approximately every five minutes. At least 30,000 children and adolescents under 18 were estimated to have MS, although incomplete pediatric reporting means the actual population may be larger. A Global Burden of Disease analysis estimated 59,345 new cases and 22,439 MS-related deaths worldwide in 2019. Mortality establishes disease severity, but pharmaceutical revenue is determined more directly by how long patients remain on therapy, how frequently they switch products and whether public or private payers reimburse treatment.

 

More than 20 disease-modifying therapies are available in the United States across oral, injectable and infusion routes. This breadth does not create equal commercial value across products. High-efficacy anti-CD20 therapies are taking patient share from older interferons, glatiramer acetate and established oral agents. Progressive-MS products are opening patient populations that previously generated limited disease-modifying treatment revenue. Generics and biosimilars are preserving treatment volume but transferring value from branded manufacturers to payers and lower-cost suppliers.

The market also includes corticosteroids and plasma exchange for acute relapses. These interventions generate episodic hospital and pharmacy demand but do not provide the recurring patient-year economics of disease-modifying therapies. The long-term market is therefore shaped principally by DMT initiation, persistence, switching, route of administration and payer access rather than the number of acute attacks treated.

 

Diagnosis Creates the Treatment Funnel but Does Not Define the Revenue Pool

MRI, cerebrospinal-fluid analysis, optical coherence tomography and other neurological assessments help confirm MS and distinguish active inflammatory disease from progressive disability. Their commercial relevance to therapeutics lies in how quickly a diagnosed patient reaches a neurologist, receives phenotype classification and qualifies for a reimbursed DMT. Delayed diagnosis reduces early treatment starts, while repeated MRI and laboratory requirements increase the cost of maintaining patients on products with strict monitoring conditions. The diagnostic procedures themselves belong to a separate market and should not be counted as therapeutic revenue.

Global prevalence also overstates the immediately monetizable population. Patients may remain untreated because of advanced age, inactive disease, contraindications, discontinuation, unaffordable copayments or the absence of licensed DMTs in their country. The Atlas of MS found access barriers in 72% of surveyed countries. Seventy percent of low-income countries reported no availability of licensed DMTs. Epidemiological need therefore converts into revenue only where specialist capacity, reimbursement and reliable medicine supply are present.

 

The United States Approaches 900,000 Patients but Active Treatment Falls with Age

The strongest published national estimate placed the US MS population between 851,749 and 913,925 people in 2017, equivalent to 337.9–362.6 cases per 100,000 population. The United States is therefore the largest directly quantified national patient opportunity in the market. Its commercial importance is amplified by branded pricing, specialist neurology networks, specialty-pharmacy infrastructure and rapid uptake of high-efficacy products. The total prevalence count must still be separated from active DMT use because older patients and those with progressive disease are substantially less likely to remain on therapy.

The Department of Veterans Affairs identified 18,353 veterans with MS in its health system during fiscal 2024. Its MS Surveillance Registry included 3,608 patients. Of these, 1,928, or 53.44%, were currently receiving a DMT, while 2,787, or 77.25%, had used a DMT at some point. The difference between lifetime exposure and current treatment indicates substantial discontinuation, aging and clinical ineligibility. It also shows why applying a uniform treatment rate to the national prevalence estimate would overstate the commercial market.

Current DMT use within the VA registry reached 82.35% among patients aged 21–30, 78.21% among those aged 31–40 and 77.08% among those aged 41–50. Utilization declined to 69.44% for patients aged 51–60, 50.52% for those aged 61–70, 29.53% for patients aged 71–80 and 16.51% among those aged 81 and older. The treated market is consequently concentrated in younger and middle-aged adults who have active inflammatory disease and longer remaining treatment duration. Products focused on progressive disability must expand eligibility among older patients to convert more of the diagnosed population into active pharmaceutical demand.

 

Infusion demand is replacing older injectable and oral prescriptions

VA prescription records document a clear shift in treatment value. Ocrelizumab records increased from 651 in fiscal 2019 to 1,705 in fiscal 2024, representing growth of approximately 162%. Ofatumumab records increased from 31 in fiscal 2021 to 334 in fiscal 2024. Ublituximab, which was not available in earlier years, reached 48 records in fiscal 2024. These figures are prescription records rather than unique patient totals, but they show how quickly anti-CD20 products have entered routine treatment.

The movement in established products was reversed. Glatiramer acetate declined from 1,914 prescription records in fiscal 2019 to 977 in fiscal 2024, a reduction of 49%. Dimethyl fumarate declined from 2,084 to 1,502, while natalizumab fell from 335 to 134. Total oral and injectable DMT records contracted from 6,403 to 4,646, a decrease of approximately 27%. Infusion records increased from 1,420 to 2,393, or nearly 69%. Infusions consequently rose from approximately 18% of VA DMT records in fiscal 2019 to 34% in fiscal 2024.

Total DMT records declined by about 10% over the same period, from 7,823 to 7,039. Revenue opportunity nevertheless moved toward higher-value therapies because the mix shifted from older genericized products to premium biologics. The US market can therefore increase in value even when the number of prescriptions remains flat or contracts. Manufacturers with high-efficacy products gain revenue per treated patient, while suppliers of mature drugs face simultaneous volume and price pressure.

Generic treatment remains important within the same system. Approximately half of DMT-treated VA patients used a generic formulation, while about one-third received a high-efficacy DMT. Conversion from branded Tecfidera to generic dimethyl fumarate generated reported VA savings of USD 24.45 million between July 2021 and February 2022. An earlier switch from Betaseron to Extavia generated USD 548,310 in savings. These examples quantify the savings available to integrated payers when interchangeable or closely related products become available.

Glatiramer acetate still supported approximately 240,000 US outpatient prescriptions for around 32,000 patients in 2023. The resulting volume shows that mature injectables retain an installed population despite declining share. FDA’s addition of a boxed warning for rare serious anaphylaxis in 2025 may increase counseling requirements and encourage switching among patients who have access to high-efficacy alternatives.

 

England Quantifies the Installed Base Available for Route Conversion

More than 150,000 people live with MS in the United Kingdom, including over 120,000 in England. Approximately 135 people are diagnosed each week. This continuing flow creates new treatment starts, but the larger near-term opportunity lies in switching established patients to more convenient formulations or more effective therapies.

NHS England identified approximately 9,000 patients who were already receiving intravenous ocrelizumab when it introduced the ten-minute subcutaneous formulation. Conventional administration could take up to four hours and was generally required twice each year. The new formulation does not create 9,000 additional Ocrevus users, but it protects a measurable installed base against Kesimpta and other lower-burden alternatives. It also releases infusion-chair and nursing capacity that can be used for oncology, immunology and other administered medicines.

The economic value extends beyond patient convenience. At the longest published administration duration, two four-hour infusions per year create up to eight hours of annual infusion time per patient before preparation and observation. A ten-minute injection sharply reduces that resource requirement. Even partial conversion of the 9,000-patient base can release tens of thousands of hospital administration hours. Roche can use those savings in payer negotiations while preserving twice-yearly product revenue.

England’s cladribine expansion offers a different commercial model. Approximately 2,000 additional patients were expected to become eligible during the first three years of broader NHS access. Cladribine requires 20 treatment days over four years. The regimen concentrates manufacturer revenue into defined treatment courses and reduces recurring hospital attendance. Merck KGaA gains new treatment starts, while the NHS limits the infrastructure cost associated with continuous infusion or monthly administration.

NICE has also converted anti-CD20 competition into a cost-comparison process. Its guidance requires the NHS to select the least expensive suitable option among ublituximab, ocrelizumab and ofatumumab after considering dosage, administration expense and confidential commercial arrangements. A product’s clinical profile is therefore only one component of access. Infusion time, home administration, rebate levels and service requirements can determine preferred status within the class.

 

Canada Provides a High-Prevalence, Long-Duration Treatment Population

Canada recorded MS prevalence of 290 per 100,000 adults aged 20 and older in fiscal 2021–22. Approximately seven in ten patients were women, and 65% of newly diagnosed adults were between 20 and 49 years old. The working-age profile supports long-duration pharmaceutical demand because patients can remain on treatment for decades and may switch several times as disease activity, tolerability and family-planning needs change.

Age-standardized prevalence increased by an average of 1.5% annually from fiscal 2011–12 through fiscal 2021–22, even though the new-case rate did not show the same increase. Longer survival and continued diagnosis are enlarging the treated patient-year base rather than creating a short-lived incidence surge. Canada is consequently attractive for products that demonstrate durable disease control and reduce time away from work, but provincial formularies and negotiated public prices restrict manufacturer revenue per patient.

Self-administered Kesimpta, course-based cladribine and infrequently administered subcutaneous Ocrevus are positioned to benefit from Canada’s geography. They reduce dependence on repeated travel to specialist infusion centers. Suppliers still need pharmacoeconomic evidence because provincial payers will compare convenience benefits against acquisition cost rather than paying a premium for route differentiation alone.

 

Australian MS Spending Is Concentrated in Medicines and Pharmacotherapy Administration

Australia had an estimated 33,300 people living with MS in 2021, equal to 130 cases per 100,000 population. The estimate increased from 25,600 in 2017, representing growth of approximately 30% over four years. Because Australian prevalence estimates use Pharmaceutical Benefits Scheme records as a major input, the figure is closely connected to treated patients. It may still omit untreated disease and does not prove continuous adherence.

Australian health-system expenditure on MS reached AUD 674.6 million in 2023–24. AIHW describes medicines as accounting for roughly seven in ten to three-quarters of spending: 69% in its detailed cost breakdown and 74% in the summary presentation. The small difference reflects reporting structure rather than a change in the market conclusion. Pharmaceutical products are the dominant economic component of Australian MS care.

Australia recorded 39,900 hospitalizations in which MS was the principal diagnosis during 2023–24. These admissions generated 45,100 procedures. Pharmacotherapy administration represented 81% of those procedures, while allied health interventions accounted for 13%. Hospital demand is therefore centered on medicine delivery and disease management rather than surgical treatment. Infusion drugs, hospital pharmacies and administration services capture most of the institutional value.

The PBS listing of Briumvi shows how reimbursement can create immediate demand for a new anti-CD20 competitor. The Australian government reported that more than 14,000 patients had accessed comparable treatment during 2024. Without subsidy, Briumvi could cost approximately AUD 15,000 per prescription. PBS support converts a clinically eligible population into an addressable market while giving the government substantial leverage over net price.

The 14,000-patient comparator base is commercially significant relative to Australia’s estimated 33,300-person MS population. It indicates that high-efficacy B-cell therapy has already penetrated a substantial share of the national market. Briumvi does not need to create demand from zero; it can compete for patients currently using Ocrevus, Kesimpta or another reimbursed DMT. Its uptake will depend on negotiated price, infusion economics and physician willingness to switch stable patients.

 

Ocrevus Has Established the Largest Single Commercial Franchise

More than 400,000 people had received Ocrevus globally by April 2025. Roche reported CHF 7.0 billion in 2025 product sales, an increase of 9%. The patient count and revenue establish Ocrevus as the largest observable product-level value pool in MS therapeutics. Its scale is supported by indications across relapsing forms and primary progressive MS, where treatment alternatives remain limited.

The cumulative treated population gives Roche advantages that cannot be reproduced quickly by a new entrant. Neurologists have extensive product experience, hospitals have established infusion protocols and payers possess large real-world utilization datasets. Switching a stable patient therefore requires a stronger efficacy, safety, convenience or cost argument than initiating a newly diagnosed patient.

Roche’s MUSETTE study of a higher Ocrevus dose did not meet its primary endpoint. That result limits dose escalation as a new growth platform and reinforces the importance of formulation and site-of-care innovation. The company’s commercial defense now relies more heavily on Ocrevus Zunovo, treatment-capacity savings and broader access to centers without extensive intravenous infrastructure.

Subcutaneous delivery also protects Ocrevus against two different threats. Kesimpta has demonstrated demand for home-administered anti-CD20 therapy, while future ocrelizumab biosimilars could compete on acquisition price. Roche can defend the reference franchise by lowering the non-drug cost of administration before biosimilar competition becomes established.

 

Kesimpta Has Created a Multibillion-Dollar Home-Administration Segment

Novartis generated USD 4.426 billion from Kesimpta in 2025, up 37% on a reported basis and 36% at constant currencies. Fourth-quarter sales reached USD 1.228 billion, increasing 29% on a reported basis. More than 187,000 patients had received the medicine since launch, and Kesimpta was approved in 94 countries.

Kesimpta continued to expand in the first quarter of 2026, producing USD 1.164 billion in sales and growing 26% at constant currencies. The performance demonstrates that self-administered high-efficacy treatment is capturing patients from both conventional oral therapies and hospital-administered biologics. It is not simply replacing older injectable products with another injection. It has created a specialty-pharmacy and home-treatment channel for B-cell therapy.

The cumulative patient count increased from more than 100,000 in March 2024 to more than 187,000 by the end of 2025. That expansion indicates that adoption is still based heavily on new starts and switches rather than price increases alone. Kesimpta’s monthly dosing requires more frequent patient engagement than twice-yearly Ocrevus, but it eliminates infusion-chair constraints and allows treatment outside major neurological centers.

Novartis must now defend that advantage against subcutaneous Ocrevus and TG Therapeutics’ planned subcutaneous Briumvi. As administration routes converge, payer contracting and evidence of adherence will become more influential. Kesimpta’s ability to sustain premium growth will depend on retaining preferred specialty-pharmacy access and demonstrating that home administration does not reduce persistence.

 

Briumvi Shows That a Focused Entrant Can Capture Anti-CD20 Share

TG Therapeutics reported USD 616.3 million in total revenue during 2025. US Briumvi net revenue reached USD 594.1 million, approximately 92% above 2024, while fourth-quarter US revenue reached USD 182.7 million. The product achieved meaningful scale despite launching into a market already occupied by Ocrevus and Kesimpta.

Briumvi’s performance confirms that anti-CD20 therapy is not a winner-takes-all category. A focused commercial organization can capture neurologist attention through competitive clinical positioning, twice-yearly maintenance dosing and concentrated sales execution. Its US dependence remains substantial. Ex-US product sales to partner Neuraxpharm reached only USD 12.8 million in 2025, compared with USD 3.7 million in 2024.

Approvals across the European Union, United Kingdom, Switzerland, Australia, Kuwait and the United Arab Emirates give Briumvi a wider regulatory footprint, but reimbursement and distribution must still convert those approvals into patient starts. The partnership with Neuraxpharm allows TG to enter international markets without building a full commercial organization in each country. It also means that TG captures less direct revenue per ex-US patient than it does in the United States.

TG projected 2026 global revenue of USD 875–900 million, including USD 825–850 million in US Briumvi revenue. The guidance implies that the company expects the US market to remain the primary growth engine. Approximately USD 100 million of additional planned expenditure relates to subcutaneous manufacturing and establishing a secondary manufacturer. Pivotal subcutaneous data are expected around late 2026 or early 2027.

The manufacturing investment is strategically necessary. Briumvi’s one-hour maintenance infusion was differentiated at launch, but ten-minute subcutaneous Ocrevus and monthly at-home Kesimpta have raised the class standard. A successful subcutaneous formulation would protect Briumvi’s growth trajectory and extend its reach beyond infusion-capable centers. Failure would leave the product exposed to competitors with more flexible treatment settings.

 

Biogen’s USD 4 Billion MS Portfolio Is Contracting Despite Stable Disease Demand

Biogen generated USD 4.039 billion in direct MS product revenue during 2025, down 7% from USD 4.350 billion in 2024. Fourth-quarter MS revenue fell 14% to USD 917 million. The decline shows that a large installed patient base does not protect legacy franchises when clinical practice and payer economics shift toward newer or lower-cost therapies.

Tecfidera revenue fell from USD 967.1 million in 2024 to USD 679.7 million in 2025, a decline of nearly 30%. Vumerity moved in the opposite direction, rising from USD 628.0 million to USD 746.8 million. Avonex declined from USD 707.5 million to USD 695.5 million, Plegridy fell from USD 260.5 million to USD 250.1 million and Tysabri decreased from USD 1.715 billion to USD 1.665 billion.

Vumerity’s growth is not sufficient to offset erosion across the wider portfolio. Tecfidera is exposed to generic dimethyl fumarate, interferons face long-term share loss and Tysabri now faces biosimilar competition. Biogen expects further contraction across most of its MS products in 2026, excluding Vumerity. The portfolio is becoming a cash-generating legacy business rather than the company’s main growth engine.

Biogen still participates economically in the expanding anti-CD20 category through its collaboration-related revenue. Its anti-CD20 program revenue increased from USD 1.750 billion in 2024 to USD 1.861 billion in 2025. This partially offsets direct product erosion and demonstrates how alliance structures can preserve exposure to a market shift even when internally commercialized brands are losing share.

 

Cenrifki Opens a New Revenue Pool in Non-Relapsing SPMS

The European Commission approved Sanofi’s Cenrifki, or tolebrutinib, in June 2026 for adults with secondary progressive MS who had experienced no relapses during the previous two years. Australia and the United Arab Emirates had also approved the medicine. The label creates a commercial category based on disability progression rather than relapse activity. These patients have historically generated limited DMT revenue because most products require active relapses or inflammatory evidence.

In the 1,131-patient HERCULES trial, tolebrutinib reduced the risk of six-month confirmed disability progression by 31% compared with placebo. Sanofi can use that result to justify premium positioning in a population with few alternatives. The commercial opportunity will be narrower than the total SPMS population because patients must satisfy disease-stage criteria and undergo liver monitoring.

Sanofi plans to begin European commercialization in Germany with a patient-support and risk-management program. Germany provides rapid access to a large specialist market, but ongoing liver tests will raise treatment cost and create operational barriers. Neurologists must identify appropriate patients, establish baseline liver status and discontinue therapy when enzyme thresholds are exceeded. The monitoring program will reduce the number of patients who can be treated outside specialist centers.

The US opportunity remains closed. FDA rejected tolebrutinib in December 2025 after identifying six Hy’s Law cases among approximately 2,700 exposed trial participants. One patient required a liver transplant and subsequently died. FDA concluded that weekly monitoring would not adequately mitigate the risk and that the submitted evidence did not clearly identify a patient population with a favorable benefit-risk balance.

The regulatory split materially limits Sanofi’s revenue ceiling. Europe and Australia give the company a first-mover position in non-relapsing SPMS, but national payers will negotiate prices and may impose strict eligibility. Exclusion from the United States removes the market with the highest branded revenue per patient. Cenrifki can expand the treated progressive-MS population, but it will remain a closely managed specialist franchise rather than a broad oral blockbuster unless the US regulatory position changes.

 

Fenebrutinib Could Shift Premium Revenue from Biologics to Oral Therapy

Roche’s fenebrutinib is the most commercially consequential late-stage asset in MS. The FENhance 1 and 2 Phase III studies included 1,497 patients with relapsing MS. Fenebrutinib reduced annualized relapse rates by 51.1% and 58.5%, respectively, compared with teriflunomide over 96 weeks. Active MRI lesions were reduced by 70.7% and 77.6%, while new or enlarging T2 lesions declined by 76.0% and 82.5%.

The FENtrepid trial compared fenebrutinib with Ocrevus in primary progressive MS and met its primary endpoint of non-inferiority. Fenebrutinib produced a numerical 12% reduction in disability-progression risk and reduced worsening of upper-limb function by 26% compared with Ocrevus. Roche plans to submit the combined relapsing and progressive MS program to regulators.

Approval across relapsing and primary progressive disease would create a high-efficacy oral product capable of competing with conventional tablets, Kesimpta, Briumvi and Ocrevus. Patients who remain on lower-efficacy oral medicines could move to a stronger option without accepting an injection or infusion. PPMS patients would gain an oral alternative to the only established disease-modifying biologic for that phenotype.

Fenebrutinib also protects Roche against disruption of its own franchise. Ocrevus can serve patients who prefer infrequent B-cell depletion, Ocrevus Zunovo can address administration burden and fenebrutinib can retain patients who prefer oral treatment. Some Ocrevus cannibalization would be likely, but Roche would keep the revenue within its portfolio rather than losing switches to Novartis, TG Therapeutics or Sanofi.

Safety will determine the breadth of the opportunity. One Hy’s Law case occurred in the fenebrutinib arm and one in the teriflunomide arm of the relapsing-MS studies. Roche also reported seven deaths in fenebrutinib-treated patients compared with one in the comparator groups, although investigators did not attribute all deaths to treatment and the causes varied. The tolebrutinib rejection will lead regulators to examine liver events and monitoring requirements closely. This cross-program scrutiny is an inference from the available regulatory and clinical evidence.

A manageable label would allow rapid switching from lower-efficacy oral products and could restore premium growth to the oral segment. Intensive laboratory requirements would weaken the convenience advantage and preserve the competitive position of established anti-CD20 biologics.

 

Generic and Biosimilar Entry Is Expanding Beyond Legacy Injectables

FDA approved Tyruko, Sandoz’s natalizumab biosimilar, in 2023 as the first biosimilar indicated for MS. The approval opened biologic price competition in a category previously protected by specialist prescribing, infusion infrastructure and safety-monitoring requirements. Uptake depends on payer policy and physician willingness to switch stable patients, but the presence of a biosimilar already strengthens payer leverage in negotiations with Biogen.

FDA approved first generics for siponimod, diroximel fumarate and cladribine in 2025. Generic competition is therefore moving beyond interferons, glatiramer acetate and dimethyl fumarate. Siponimod is used in active secondary progressive disease, while cladribine offers a differentiated course-based regimen. Price pressure is reaching products that previously occupied more defensible clinical niches.

Generics will not eliminate branded demand. Patients may remain on established brands because of stable disease control, payer authorization or physician familiarity. The principal commercial impact is lower net price and stronger formulary control. Manufacturers must increasingly defend brands through patient-support services, tolerability, formulation improvements and evidence that switching could disrupt adherence.

 

Product Segmentation Now Reflects Three Different Economic Models

Monoclonal antibodies and other high-efficacy biologics

Ocrevus, Kesimpta and Briumvi form the primary anti-CD20 category. Tysabri, Tyruko and Lemtrada occupy additional high-efficacy positions. These products capture the highest observable revenue per treated patient but require stronger safety management, specialty distribution or administered-care infrastructure. Ocrevus generated CHF 7.0 billion, Kesimpta produced USD 4.426 billion and US Briumvi revenue reached USD 594.1 million in 2025.

Premium and mature oral therapies

The oral segment includes teriflunomide, dimethyl fumarate, diroximel fumarate, monomethyl fumarate, fingolimod, siponimod, ozanimod, ponesimod and cladribine. Cenrifki has now added a progressive-MS opportunity, while fenebrutinib could introduce high-efficacy oral competition across relapsing and primary progressive disease. Mature oral products provide large prescription volumes but are becoming more price-sensitive as generic availability expands.

Legacy self-injected products

Interferon betas and glatiramer acetate retain patients who value long safety experience or are stable on existing therapy. Their market position is contracting as physicians initiate high-efficacy products earlier and payers prefer generics. VA records show glatiramer acetate prescriptions falling by 49% between fiscal 2019 and fiscal 2024, providing a quantified example of the structural decline.

Acute-relapse medicines and procedures

Oral prednisone, intravenous methylprednisolone and plasma exchange address acute attacks rather than long-term disease modification. They create hospital, pharmacy and procedure demand when relapses occur, but their episodic use makes them a secondary revenue segment. Wider use of effective DMTs may reduce relapse-treatment volume even as the overall therapeutics market grows.

 

Regional Growth Will Follow Different Commercial Models

North America will remain the highest-value regional market. The United States has a patient population approaching 900,000, strong specialist infrastructure and rapid uptake of premium biologics. It also has aggressive prior authorization, growing generic exposure and a regulator willing to reject products with unresolved safety risks.

Europe offers the strongest immediate opportunity for non-relapsing SPMS following the Cenrifki approval. National health systems can identify patients through centralized neurology networks, but health-technology assessments and negotiated prices will constrain revenue per treatment. England’s 9,000-patient Ocrevus base demonstrates the scale available for formulation conversion.

Canada provides long treatment duration because 65% of new adult diagnoses occur between ages 20 and 49. Its public-payer structure favors therapies that demonstrate lower lifetime resource use rather than products relying only on a premium list price.

Australia combines a 33,300-patient population with AUD 674.6 million in annual MS expenditure. Medicines account for roughly seven in ten to three-quarters of that spending, while 81% of principal-diagnosis hospital procedures involve pharmacotherapy administration. PBS reimbursement remains the principal gateway to meaningful product uptake.

Lower-income markets contain substantial unmet need but limited premium revenue potential. WHO’s addition of cladribine, glatiramer acetate and rituximab to its Essential Medicines List supports growth through public procurement, biosimilars and affordable established therapies. These markets are more likely to generate volume for lower-cost suppliers than Ocrevus- or Kesimpta-level revenue per patient.

 

Competitive Outlook Through 2032

Roche holds the strongest integrated position. Ocrevus contributes CHF 7.0 billion in annual revenue and has treated more than 400,000 people. Ocrevus Zunovo protects the franchise through faster administration, while fenebrutinib could retain patients who prefer oral therapy.

Novartis has built Kesimpta into a USD 4.426 billion franchise with more than 187,000 cumulative patients across 94 countries. Its next challenge is defending home-administration leadership as Roche and TG Therapeutics develop lower-burden formulations.

TG Therapeutics has demonstrated that a focused entrant can capture share, producing USD 594.1 million in US Briumvi revenue during 2025. Its USD 875–900 million 2026 revenue guidance depends heavily on US growth, while subcutaneous development and the Neuraxpharm partnership determine its longer-term geographic reach.

Biogen retains USD 4.039 billion in direct MS product revenue, but the portfolio contracted 7% in 2025. Tecfidera lost nearly 30% of annual revenue, Tysabri declined and interferon products continued to weaken. Vumerity and collaboration revenue provide partial protection but do not reverse the migration toward anti-CD20 treatment.

Sanofi has opened a new European and Australian market in non-relapsing SPMS with Cenrifki. The US rejection and liver-monitoring burden limit its immediate global potential. Commercial performance will depend on how many progressive patients meet payer criteria and remain on treatment after surveillance requirements are applied.

Sandoz and generic manufacturers are gaining strategic leverage as biosimilar and first-generic approvals extend into natalizumab, siponimod, diroximel fumarate and cladribine. Their opportunity lies in payer contracts, reliable supply and treatment volume rather than premium clinical differentiation.

The strongest market growth through 2032 will come from four quantified transitions. High-efficacy infusion records are replacing older oral and injectable prescriptions. Established anti-CD20 patients are moving toward subcutaneous and home-based administration. Cenrifki is converting a portion of non-relapsing SPMS into a reimbursed pharmaceutical segment. Fenebrutinib could create high-efficacy oral competition across relapsing and primary progressive disease.

These transitions will increase total pharmaceutical value while concentrating growth among a limited number of franchises. Products that reduce disability progression, release hospital capacity or lower total treatment cost will capture new patients and switches. Mature brands without those advantages will retain some prescription volume but surrender revenue to anti-CD20 therapies, generics, biosimilars and payer-directed alternatives.

 

Multiple Sclerosis Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 30.65 Billion
Revenue Forecast in 2032	USD 48.58 Billion
Overall Growth Rate	CAGR of 6.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Drug Class	Immunomodulators; Oral Agents; Monoclonal Antibodies; Others
By Route of Administration	Oral; Injectable; Intravenous Infusion
By Disease Type	Relapsing-Remitting MS; Secondary Progressive MS; Primary Progressive MS
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Rising Adoption of High-Efficacy Disease-Modifying Therapies	Increasing use of monoclonal antibodies, biologics, and advanced disease-modifying therapies is supporting market expansion through improved disease control and treatment personalization.
Market Drivers – Progressive Multiple Sclerosis Treatment Innovation	Development of therapies targeting progressive disease stages is expanding commercial opportunities beyond traditional relapse-focused treatment approaches.
Market Drivers – Growth of Oral and Self-Administration Therapies	Rising preference for convenient treatment formats, reduced infusion dependence, and improved patient experience is accelerating demand for oral and alternative administration routes.
Customization Option	Available upon request